Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Editorial

Who would stay with Woodford?
Woodford Investment Management has had nothing but bad luck for months and there is a looming question as to whether the firm can survive.
Europe’s position narrows as disruption unfolds
Social network Facebook’s plans to launch the Libra blockchain and native cryptocurrency, its custodial wallet and subsidiary Calibra, programming language Move and its governing body the Libra Association based in Geneva, Switzerland, certainly took most of the attention this month.
The storm is up and all is on the hazard
July issue editorial by Thierry Heles, editor, Global University Venturing
Revolutionising the learning experience – the story of BibliU
Tao Mantaras, co-founder and chief financial officer of BibliU, tells GUV editor Thierry Heles how his company is fundamentally changing academic publishing and the learning experience.
A lack of vision will come to haunt us all
May issue editorial by Thierry Heles, editor, Global University Venturing
Big deal: Syncona composes Quell with $46m series A
Quell Therapeutics will develop treatments for conditions such as solid organ transplant rejection and has also secured capital from UCL Technology Fund.
Big deal: Verve shows $58.5m series A enthusiasm
The series A, led by corporate venturing unit GV, may not have been last week’s largest deal, but Verve’s tie-up with fellow Harvard spinout Beam Therapeutics tells an intriguing story.
Dare to fail greatly
March issue editorial by editor Thierry Heles.

Other News

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Anaveon proves UZH fund model works
Anaveon emerged out of University of Zurich in late 2017 with the support of Novartis-backed UZH Life Sciences Fund and the corporate has now also invested directly.
Big deal: Nightstar shines bright in $800m acquisition
Nightstar Therapeutics, based on Oxford research, stands to receive $800m from Biogen in an acquisition deal that comes a year and a half after completing a $75m IPO.
I license, therefore I am
February 2019 issue editorial by editor Thierry Heles
Lighting the match
January 2019 issue editorial by Thierry Heles, editor, Global University Venturing
Big deal: Stanford-StartX Fund reaches the end
The Stanford University-backed fund will halt new investments from July, seemingly as the accelerator reaches financial stability but in the midst of a legal battle.

Editor's Picks

Who would stay with Woodford?
Woodford Investment Management has had nothing but bad luck for months and there is a looming question as to whether the firm can survive.
Revolutionising the learning experience – the story of BibliU
Tao Mantaras, co-founder and chief financial officer of BibliU, tells GUV editor Thierry Heles how his company is fundamentally changing academic publishing and the learning experience.
A lack of vision will come to haunt us all
May issue editorial by Thierry Heles, editor, Global University Venturing
Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
test reg

Login